MSBase Registry

MSBase is an international real-world Neuroimmunology registry open to all practicing neurologists and their healthcare teams.

[Sudarshini Ramanathan @darshi_r]

⁦Fantastic presentation from ⁦@Benjamin_Trewin⁩ regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD onset delaying time to first relapse @ECTRIMS. Great audience discussions ⁦@syd_health⁩ ⁦@kids_research⁩ ⁦⁦⁦

[ECTRIMS @ECTRIMS]

#ECTRIMS2024 | Welcome to the 1st day of the 40th Congress of ECTRIMS! Thank YOU for being a vital part of this journey. 📽️ Watch MS experts Prof. Tobias Sejbæk, Prof. Jette Frederiksen, and Prof. Melinda Magyari (@melindamagyari), present today’s Daily Highlights. 👇 👇 👇

[ECTRIMS @ECTRIMS]

🚨 LIVE in 15 minutes! Join Scientific Session 1 on the revised diagnostic criteria w/ MS experts, incl. @xmontalban, @Marcello_Moccia, @DrWBRO, @kuchling_j, Fiorella Guido, @held_fr, chaired by @MarTintore & @Calabre04804429.
🔗 Join here: https://t.co/3Ad9lc4tUW

[MSBase Registry @MSBase_Registry]

MSBase is 20 years old!! and holds >110,000 patient records. Dedicated clinicians all over the world contributes data with >110 papers, many that have changed clinical practice. We are so grateful to all the supporters of our mission to improve the lives of people with #MS.

[MSBase Registry @MSBase_Registry]

We are here and ready! Come and visit the MSBase team @ECTRIMS to get updates on 20 years of real-world data and evidence in #MS.

[Dr Kish Mankad @drmankad]

Your roadmap for Autoimmune Encephalitis. A useful slide being shared from our UK Childhood Neuroinflammatory Disorders meeting, put together by Dr Michael Eyre.

[Journal of Neurology, Neurosurgery and Psychiatry @JNNP_BMJ]

📢🔥Take note! Data from the massive @MSBase_Registry dataset shows that secondary and primary progressive MS disease differ in disease onset and course. This is super important to consider when studying disease modifying therapies.

https://t.co/xhm0d5sbkI @izanne_roos

[AnnekeVdWalt @anneke_vdw]

Fantastic catching up with friends &colleagues from the #BigMS data registries. Collectively, we manage ~300,000 patient records. “Harmonise the people, harmonise the data” @melindamagyari @dhorakova @TrojanoMaria @JiDrahota @VukusicS @MSBase_Registry @janhillert and many more!

[MSBase Registry @MSBase_Registry]

Festive greetings and a joyous Christmas from the MSBase Management team, to our amazing MSBase Ops Team, SLG committees, Board and valued Members - wishing you all a safe and happy holiday season.

[Monash STM Neuroscience @STMneurosci]

New published data @MonashCCS @Alfred_Research @HelmutButz @MSBase_Registry to support clinical decision making for patients with #MultipleSclerosis who need to switch #treatment to fully control their disease. Read more👇
https://t.co/sZmnORnJsD

[Dr. Brandon Beaber @Brandon_Beaber]

Is HSCT really that good? This analysis at #ECTRIMS2022 (unrandomized) found HSCT is better than gilenya but similar in efficacy to ocrevus and tysabri (in relapses, disability progression), though improvement was more common with HSCT. https://t.co/1Ml4Rz5grW

[Klaus Schmierer @KlausSchmierer]

🌷Late breaking news at #ECTRIMS2022 @Iamsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizumab in #progressive #MS revealed no difference in efficacy. Early treatment best, applies to both💡

[Assoc Professor Vilija Jokubaitis @vjokubaitis]

Izanne Roos presenting a non-inferiority study of ocrelizumab and rituximab on behalf of the @MSBase_Registry and the Danish registry

[Barry Singer MD 🧠 @drbarrysinger]

Kalincik @MSBase_Registry study: Propensity-matched #progressive #MS patients treated with AHSCT or natalizumab. No difference on relapse rates and disability progression. #ECTRIMS2022

[Assoc Professor Vilija Jokubaitis @vjokubaitis]

Visiting the hard working team at the @MSBase_Registry booth at #ECTRIMS2022 thank you to Charlotte Sartori, Pam Farr, Rein Moore, and Dusko Stupar for their amazing work on the operations team making the magic happen 🙌���

[Ruth Dobson @drruthdobson]

Made it into the pregnancy session in time for a really relevant talk by Annika Anderson - low transfer of CD20 molecules into mature breast milk (ie post colostrum) with infant dose <1%

[UKMSRegister @UKMSRegister]

Excellent talk by @annalauralerede from at #ECTRIMS2022 presenting on the different ways MS can progress over time (using MS Register data) and how important online registers are for tracking disease long term 👍🏼

[Ellen Mowry @EllenMowryMD]

Dr. Nicole Bou Rjeily starting a great presentation at ECTRIMS. Strong scientist and future neurologist!

@IntNatlWiMS @ECTRIMS

[MSBase Registry @MSBase_Registry]

Chao Zhu representing @MSBase_Registry data @ECTRIMS #DMT efficacy. Congratulations to all MSBase investigators involved!

[Ruth Dobson @drruthdobson]

In prospectively reported cases, no increased risk of spontaneous pregnancy loss, preterm birth, ectopic pregnancy. Rate of elective abortion in exposed pregnancies decreasing over time. Very few major congenital abnormalities - with a similar distribution to expected